Vaxcyte, Inc. (NASDAQ:PCVX) Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its holdings in Vaxcyte, Inc. (NASDAQ:PCVX) by 3.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 1,341,773 shares of the company’s stock after acquiring an additional 45,936 shares during the period. Charles Schwab Investment Management Inc. owned 1.08% of Vaxcyte worth $109,838,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in PCVX. CIBC Asset Management Inc boosted its stake in Vaxcyte by 3.6% in the 3rd quarter. CIBC Asset Management Inc now owns 3,136 shares of the company’s stock worth $358,000 after buying an additional 110 shares during the last quarter. Smartleaf Asset Management LLC increased its position in Vaxcyte by 188.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock worth $33,000 after purchasing an additional 260 shares during the last quarter. KBC Group NV raised its stake in Vaxcyte by 13.6% during the third quarter. KBC Group NV now owns 2,683 shares of the company’s stock worth $307,000 after purchasing an additional 322 shares during the period. Amalgamated Bank boosted its holdings in shares of Vaxcyte by 8.6% in the 3rd quarter. Amalgamated Bank now owns 4,081 shares of the company’s stock valued at $466,000 after purchasing an additional 322 shares during the last quarter. Finally, Whipplewood Advisors LLC purchased a new stake in shares of Vaxcyte during the 4th quarter valued at $28,000. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on PCVX shares. The Goldman Sachs Group began coverage on Vaxcyte in a research note on Friday, December 20th. They issued a “buy” rating and a $135.00 price objective on the stock. Guggenheim reiterated a “buy” rating and set a $160.00 price objective on shares of Vaxcyte in a research note on Wednesday, February 26th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $140.00 target price on shares of Vaxcyte in a research note on Wednesday, February 26th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $147.50.

Vaxcyte Trading Down 4.9 %

Shares of NASDAQ PCVX opened at $71.18 on Friday. The company has a market cap of $9.17 billion, a price-to-earnings ratio of -15.47 and a beta of 1.02. The stock’s 50 day simple moving average is $83.33 and its 200 day simple moving average is $94.62. Vaxcyte, Inc. has a 12-month low of $58.10 and a 12-month high of $121.06.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.16) by $0.14. As a group, equities analysts forecast that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Grant Pickering sold 2,366 shares of the company’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $92.25, for a total value of $218,263.50. Following the completion of the sale, the chief executive officer now owns 136,215 shares of the company’s stock, valued at $12,565,833.75. This represents a 1.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Jim Wassil sold 8,000 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $73.27, for a total transaction of $586,160.00. Following the completion of the transaction, the chief operating officer now owns 154,931 shares of the company’s stock, valued at $11,351,794.37. This represents a 4.91 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 56,616 shares of company stock worth $4,768,521. 3.10% of the stock is owned by company insiders.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.